Coverage / PRTA / Trade Card

PRTA

Prothena Corporation PLC

OPPORTUNISTIC BUY 2026-08-08 Data 35 days old USD 8.76 Healthcare - BiotechnologyAWAIT ENTRY
ACTIONABLEMethodology gates passed
62

Position levels

Currenttoday
USD 8.76
Buy <=wait / entry
USD 7.33
Trim >=take some off
USD 11.00
Thesis breakA negative pivotal readout on a registrational amyloid asset, an unfavourable FD...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case29%100 / 10029.0
Base case50%62 / 10031.0
Bear case21%10 / 1002.1
Weighted conviction62 / 100 - OPPORTUNISTIC BUY

Top risks

  • Strategic partnerships with Roche, Novo Nordisk and Bristol Myers Squibb providing development support
  • Analyst consensus Hold rating with average price target of $21.4 representing 144% upside
  • TTM revenue of $57.9m with 125% 5-year CAGR and next estimate $72.1m
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.